¶ Piracetam
¶ Overview
Piracetam is the first "nootropic" drug, synthesized in 1964 by Dr. Corneliu Giurgea. It established the criteria for nootropics: enhancing learning/memory, protecting the brain against injury, and lacking sedation or toxicity. It is widely prescribed in Europe and Asia for cognitive impairment, vertigo, and myoclonus, though it is sold as a dietary supplement in the US.
¶ Mechanism of Action
Piracetam's precise mechanism remains partially elusive, but the leading theory is membrane fluidity:
- Membrane Fluidity: Piracetam binds to the polar heads of phospholipids in the neuronal membrane, restoring fluidity in aged or damaged cells. This improves the function of membrane-bound receptors (like NMDA and acetylcholine receptors) and ion channels[1].
- Mitochondrial Function: It improves mitochondrial permeability and ATP production, particularly in aged brains.
- Microcirculation: It has rheological effects, decreasing platelet aggregation and improving blood flow without being a vasodilator.
¶ Clinical Evidence
- Cognitive Decline: A Cochrane review (2001) and subsequent meta-analyses found that Piracetam significantly improved global impression of change in older patients with cognitive impairment, though results on specific memory tests were mixed[2].
- Stroke Recovery: Large trials (e.g., PASS) failed to show efficacy in acute stroke mortality but suggested benefits for post-stroke aphasia (language recovery) when used long-term.
¶ Dosage and Usage
- Dosage: Standard clinical doses are high, typically 1,200 mg to 4,800 mg per day, divided into 2-3 doses.
- Choline Synergy: It is commonly recommended to take a choline source (like Alpha-GPC or CDP-Choline) with Piracetam to prevent "racetam headaches" and support acetylcholine synthesis, though this is primarily based on user experience and animal models.